

Application No.: 09/824,647
Amendment dated August 21, 2003
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

This listing of claims will replace all prior versions, and listings, of claims in the application:

Amendments To The Claims:

Claims 1-27 (cancelled).

1 ~~28.~~ (Previously presented) A composition comprising an isolated antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody has anti-tumorigenic activity.

2 ~~29.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

3 ~~30.~~ (Previously presented) A composition according to claim ~~28~~, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

4 ~~31.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

5 ~~32.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

6 ~~33.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

7 ~~34.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

8 ~~35.~~ (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

Application No.: 09/824,647
Amendment dated August 21, 2003
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

9 ~~38~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

10 ~~39~~. (Previously presented) A composition according to claim ~~28~~, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16. *a protein encoded by*

11 ~~38~~. (Previously presented) The composition of claim ~~28~~, wherein said antibody is a chimeric antibody comprising a plurality of portions, wherein at least one portion is derived from a human.

12 ~~39~~. (Previously presented) The composition of claim ~~28~~, wherein at least one portion is derived from a non-human animal.

13 ~~40~~. (Previously presented) The composition of claim ~~28~~, wherein said non-human animal is a mouse.

14 ~~41~~. (Previously presented) The composition of claim ~~28~~, wherein said at least one portion is a constant region.

15 ~~42~~. (Previously presented) The composition of claim ~~28~~, wherein said at least one portion is a variable region.

16 ~~43~~. (Previously presented) The composition of claim ~~28~~, further comprising a cytotoxic molecule, wherein said antibody is attached to said cytotoxic molecule.

17 ~~44~~. (Previously presented) The composition of claim ~~43~~, wherein said cytotoxic molecule is selected from the group consisting of toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides.

18 ~~45~~. (Previously presented) The composition of claim ~~43~~, wherein said cytotoxic molecule is an oncotoxin.

Application No.: 09/824,647
Amendment dated August 21, 2003
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

19 46. (Previously presented) A composition comprising a monoclonal antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said monoclonal antibody has anti-tumorigenic activity.

19 20 47. (Previously presented) A composition according to claim 46, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

19 21 48. (Previously presented) A composition according to claim 46, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

19 22 49. (Previously presented) A composition according to claim 48, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

Claims 50-55 (Cancelled).

*See Examiner's Amendment
20030730*
23 56. (Previously presented) A method of inhibiting tumorigenic activity, comprising obtaining an antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody inhibits tumorigenic activity; and contacting said antibody with the protein encoded by SEQ ID NO: 16.

23 57. (Previously presented) A method according to claim 56, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

23 58. (Previously presented) A method according to claim 56, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

23 59. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 3.

Application No.: 09/824,647
Amendment dated August 21, 2003
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

23
27. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 4.

28
28. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 5.

29
29. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 6.

30
30. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 7.

31
31. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 16.

32
32. (Previously presented) A method of inhibiting tumor cell proliferation, comprising administering to a tumor cell an effective amount of an antibody capable of binding to an epitope encoded by SEQ ID NO: 16, wherein said antibody inhibits tumor cell proliferation.

33
33. (Previously presented) A method according to claim 32, wherein said tumor cell is selected from the group consisting of breast, ovarian, adipose, brain, liver, and kidney cells.

34
34. (Previously presented) A method according to claim 32, wherein said antibody inhibits tumor cell proliferation by at least about 50%.

35
35. (Previously presented) A method according to claim 32, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V and anti-A14R antibodies.

Application No.: 09/824,647
Amendment dated August 21, 2003
Reply to Office Action dated July 15, 2003

Docket No.: A7542.0000/P001-E

36 65. (Previously presented) A method according to claim *65*, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

37 70. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

38 71. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

39 72. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

40 73. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

41 74. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

42 75. (Previously presented) A method according to claim *65*, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16. *a protein encoded by*